Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes

By Villaseca P   Hormaza P   Cárdenas I   Oestreicher E   Arteaga E  

The European Journal of Contraception and Reproductive Health Care, Vol. 9, Iss. 3, 2004-09 ,pp. : 155-165

Informa Healthcare

Access to resources Recommend Favorite

Effect of ethinyl estradiol–cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome

By Karakurt Feridun   Carlioglu Ayse   Kaygusuz Ikbal   Gumus Ilknur   Uz Burak   Akdeniz Derya  

Archives of Gynecology and Obstetrics, Vol. 289, Iss. 1, 2014-01 ,pp. : 135-140

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of combined ethinyloestradiol (0.035 mg) and cyproterone acetate (2 mg) in acne and hirsutism in women with polycystic ovary syndrome

By Falsetti L.   Ramazzotto Francesca   Rosina Barbara  

Journal of Obstetrics & Gynaecology, Vol. 17, Iss. 6, 1997-12 ,pp. : 565-568

Informa Healthcare

Access to resources Recommend Favorite

The combination of ethinylestradiol/cyproterone acetate is temporarily withdrawn from the market in France. Is the measure justified?

By Chabbert-Buffet Nathalie  

The European Journal of Contraception and Reproductive Health Care, Vol. 18, Iss. 2, 2013-04 ,pp. : 75-78

Informa Healthcare

Access to resources Recommend Favorite

Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

By Cataldo N.A.   Abbasi F.   McLaughlin T.L.   Lamendola C.   Reaven G.M.  

Fertility and Sterility, Vol. 76, Iss. 5, 2001-11 ,pp. : 1057-1059

Elsevier

Access to resources Recommend Favorite